BioSpace News Archive

PMV Pharmaceuticals, Inc. (Nasdaq: PMVP) today announced that it will present updated Phase 1 data from the ongoing Phase 1/2 PYNNACLE study of PC14586 in a late-breaking poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place October 11-15, 2023, in Boston, Massachusetts.

Franklin Mountain Medical announced today that the Dib UltraNav Transseptal Catheter System, which houses a needle and ultrasound in one system for use in atrial transseptal procedures and delivery of catheters, has now been successfully used in 15 human cases, at major cardiology hospitals in Arizona and Minnesota.

Neurolief, a global medical device company that is delivering life-changing neurotechnology innovations, today announced the appointment of Steve Beller, an experienced senior commercial leader in neurotechnology, as Chief Commercial Officer (CCO).

STEMCELL Technologies, Canada’s largest biotechnology company, is releasing its first annual sustainability report today.

Covalon Technologies Ltd., a leader in advanced medical technologies, announced its participation in the American Nurses Credentialing Center Magnet Conference.

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, function, and independence in people with spinal cord injury, today announced that it will host a webcast to discuss its Q3 2023 business highlights.

Cellipont Bioservices and Evia Bio announced today a strategic partnership to launch a Cryopreservation Excellence Center (CryoX) at Cellipont Bioservices cGMP cell therapy manufacturing facilities in The Woodlands, TX (Houston) in 2024.

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, shares the invitation for the company’s Capital Markets Day on October 17, 2023.

Genentech, a member of the Roche Group, announced results from the Phase IV CHIMES trial evaluating Ocrevus® in Black and Hispanic / Latinx people with relapsing multiple sclerosis.

Data from the ongoing Phase II open-label extension (OLE) study of evobrutinib show sustained clinical efficacy and a safety profile that remains consistent with that previously reported over five years of therapy - the longest follow-up of any Bruton’s tyrosine kinase inhibitor (BTKi) in multiple sclerosis (MS) studies Additional Phase II OLE data show significant and clinically meaningful improvements on mental health and quality of life measures in study participants with relapsing